JHL Biotech and Switzerland-based Selexis SA have signed a non-exclusive strategic agreement to provide services for the development and cGMP manufacture of biologic drugs. The alliance will have a special focus on delivering high-quality biologics to the Chinese market.
The alliance will allow customers to go from drug candidate DNA to active pharmaceutical ingredient (API), and into clinical development and commercialization. Selexis will provide the fully documented SURE CHO-M mammalian clonal cell lines, and JHL Biotech will provide process development and cGMP manufacturing at its facilities in Hsinchu, Taiwan and Wuhan, China.
"Biopharmaceutical companies now can turn to JHL Biotech and Selexis for a reliable, rapid process to get products to market in China and the rest of the world," said Racho Jordanov, JHL Biotech's chief executive officer, co-founder, and president. "Making world-class biologics more affordable just got easier through the partnership of JHL Biotech and Selexis."
"We are especially pleased at how fast we were able to provide JHL's customer a clonal cell line expressing over 5 g/L at Selexis," said Dr. Igor Fisch, chief executive officer, Selexis SA. "By seamlessly combining JHL Biotech and Selexis' unique technologies and know-how, it is now possible to save our customers both time and money with their biologic development programs. Moreover, the JHL Biotech and Selexis alliance will allow biopharmaceutical companies to cost effectively develop safe biologic drugs for the Chinese market."